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Adipose tissues provide circulating nutrients and
hormones. We present in vivo mouse studies high-
lighting roles for Wnt signals in both aspects of
metabolism. b-catenin activation in PPARg-express-
ing fat progenitors (PBCA) decreased fat mass and
induced fibrotic replacement of subcutaneous fat
specifically. In spite of lipodystrophy, PBCA mice
did not develop the expected diabetes and hepatos-
teatosis, but rather exhibited improved glucose
metabolism and normal insulin sensitivity. Glucose
uptake was increased in muscle independently of
insulin, associated with cell-surface translocation of
glucose transporters and AMPK activation. Ex vivo
assays showed these effects were likely secondary
to blood-borne signals since PBCA sera or condi-
tioned media from PBCA fat progenitors enhanced
glucose uptake and activated AMPK in muscle
cultures. Thus, adipose progenitor Wnt activation
dissociates lipodystrophy fromdysfunctional metab-
olism and highlights a fat-muscle endocrine axis,
which may represent a potential therapy to lower
blood glucose and improve metabolism.
INTRODUCTION
The ability to maintain metabolic homeostasis was a key step
during the evolutionary transition to multicellularity and tissue
specification. To meet the energy demands of individual cells,
organisms have adapted to distribute nutrients through circula-
tory systems (Strilic et al., 2010). Carbohydrates (e.g., glucose)
are a main circulating nutrient to preserve cellular energy
balance. Intravascular and intracellular levels of carbohydrates
are regulated by conserved, relatedmechanisms, such as insulin
and AMP kinase (AMPK) signaling (Kahn et al., 2005). In addition
to mechanistic conservation, evolutionary pressures have main-
tained homeostasis through dynamic interactions of tissues492 Cell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc.including neural, muscle, and fat lineages (Galic et al., 2010;
Huang and Czech, 2007; Morton et al., 2006).
Muscles are a major source of glucose uptake and utilization.
Indeed, insulin resistance and impaired glucose uptake in
muscle are hallmarks of type II diabetes (DeFronzo and Tripathy,
2009; Fujii et al., 2006; Garvey et al., 1998; Zierath et al., 1996). In
muscle, insulin and AMPK signaling activate glucose uptake by
stimulating translocation of glucose transporters (e.g., Glut4)
from the cytoplasm to the plasmamembrane (Huang and Czech,
2007; Lemieux et al., 2003; Steinberg and Kemp, 2009).
White adipose tissues also regulate homeostasis as under-
scored by the metabolic perturbations: dyslipidemia, ectopic
fat deposition, insulin resistance, and diabetes, observed in
obesity and lipodystrophy (Fiorenza et al., 2010; Garg, 2004;
Must et al., 1999; Savage, 2009). Even though adipose tissues
plays a pivotal role in metabolism, its cellular lineage and in vivo
development are just beginning to be elucidated (Zeve et al.,
2009). Wnt signaling has been implicated, based upon in vitro
and transgenic studies, as inhibiting murine fat differentiation
(Bennett et al., 2002; Longo et al., 2004; Ross et al., 2000; Wright
et al., 2007).
To dissect the Wnt pathway in adipose lineage formation we
evaluated canonical, cell-autonomous Wnt signaling within
murine mature adipocytes and adipose progenitor cells (Rode-
heffer et al., 2008; Tang et al., 2008, 2011; Zeve et al., 2009).
Using two different drivers, aP2-Cre and PPARg-tTA; TRE-Cre,
we drove expression of a constitutively active form of b-catenin,
using a conditional allele of the endogenous locus, at various
stages in the adipose lineage. We found that activating Wnt
signaling within mature adipocytes with aP2-Cre (termed
A-BCA for adipocyte b-catenin activated) did not change
adiposity or metabolism. These results contrast with those
produced using the PPARg-tTA; TRE-Cre driver in which Wnt
signaling was altered in the adipose progenitor cells and then
throughout the lineage. These mice (termed P-BCA for progen-
itor b-catenin activated) had lipodystrophic levels of fat, hypertri-
glyceridemia, and a paucity of adipocytes. There was a regional
specificity to this adipocyte loss; subcutaneous depots had
fibrotic replacement, while visceral depots did not. Despite the
paucity of adipocytes and evident hypertriglyceridemia, P-BCA
mutants were protected from hepatic steatosis, a hallmark of
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more, P-BCA mice, in contrast to other forms of lipodystrophy,
displayed improved glucose metabolism, with muscles utilizing
two to four times more glucose than controls. These changes
were independent of insulin. Rather, increased glucose uptake
was caused tissue nonautonomously with activation of AMPK
and translocation of glucose transporters to the cell surface in
muscles. The increase in glucose uptake was apparent ex vivo
immediately after placing P-BCA mutant muscles in culture,
but thereafter was reversible, indicating that the increase in
glucose uptake was not intrinsic to the muscles. Indeed, mutant
sera increased glucose uptake and AMPK activity of cultured
muscles, pointing to the presence of a humoral factor. A similar
activity was also present in conditioned media of P-BCA mutant
adipose stromal vascular (SV) cells, in which adipose progenitors
reside, supporting the idea that altered adipose progenitors may
be the source of the signal. Thus, the P-BCA model illuminates
a possible therapeutic method to improve metabolism in the
face of adipose dysfunction and diabetes.
RESULTS
Mice with b-Catenin Activated in Mature Adipocytes
Have Normal Metabolism
MacDougald and colleagues reported that transgenic expres-
sion of the secreted Wnt10b ligand from mature adipocytes
using the FABP4/aP2 promoter resulted in an 50% decrease
in total body fat (Longo et al., 2004). To examine cell-autono-
mous canonical Wnt in mature adipocytes, we crossed our
described aP2-Cre mice (Figure 1A) (Tang et al., 2008) with a
conditional allele of b-catenin (fBC for floxed b-catenin) in which
Cre expression activatesWnt signaling, generating aP2-Cre; fBC
(A-BCA) mice. Previous studies, confirmed here, showed that
this Cre is highly expressed in mature adipocytes, but not in
adipose progenitors (Figures S1A, S1B, S2C, and S2D) (Tang
et al., 2008, 2011; Zeve et al., 2009). Western blots indicated
aP2-Cre; fBC combination was effective; the activated, faster
migrating form of b-catenin was detected in adipose depots of
A-BCA mutant, but not control, adipose tissues (Figure 1B). To
further examine effectiveness and specificity, we performed
qPCR of the floated adipocyte fraction and the stromal vascular
fraction (SVF), which contains adipose progenitors. We found
increased Wnt target gene expression in the floated adipocyte
fraction adipocytes of A-BCAmice, but not in their SVF, contain-
ing adipose progenitors (Figure 1C).
Four-month-old A-BCA mutant mice fed normal chow had no
discernable subcutaneous or visceral adipose or metabolic
phenotypes (Figure 1). Controls and A-BCA mutants had equal
amounts of fat based upon magnetic resonance imaging (MRI)
scans, nuclear magnetic resonance (NMR) fat content analyses,
and adipose depot weight, size, and morphology (Figures 1D–
1G). Histological analyses of the inguinal (IGW) and perigonadal
(PGW) adipose depots revealed no apparent changes (Fig-
ure 1H). We did detect fibrosis in subdermal tissue (Figure 1I)
similar to previous data of cell nonautonomous Wnt activation
models in which expression of Wnt10b is driven by aP2 (Longo
et al., 2004). The size and morphology of other organs such as
heart and kidney were unchanged (Figure S1C; not shown).
Serum analysis showed no significant difference in adiponectin,Cleptin, triglyceride (TG), or insulin levels (Figures 1J and 1K). Fed
and fasted blood glucose levels and glucose tolerance tests
(GTTs) were unaltered (Figures 1L and 1M). Notably, the
normalcy is dissimilar from previous data of cell nonautonomous
Wnt activation models in which expression of Wnt10b driven by
aP2 resulted in an approximately 50% reduction in subcuta-
neous and visceral fat (Longo et al., 2004; Wright et al., 2007).
The differences of the two murine phenotypes may derive from
the secretory nature of Wnt10b and its possible effects on other
cell types present in adipose tissue such as endothelial cells and
adipose progenitor cells, or cells affected at a distance.
Mice with b-Catenin Activation in the Progenitor
Compartment Have Severe Loss of Adiposity
We next examined the effects of cell-autonomous Wnt pathway
activation in adipose progenitor cells (Figure 2). For this, we
turned to a strain, PPARg-tTA; TRE-Cre, in which Cre is ex-
pressed in adipose lineage cells (Figures S2A—S2C) (Tang
et al., 2008, 2011; Zeve et al., 2009). Unexpectantly, Cre is ex-
pressed in similar levels between SV cells and mature adipo-
cytes, possibly because tTA is saturating, inducing maximal
Cre expression in the trigenic system (Figure S2C) (El-Bizri
et al., 2008; Sakahara et al., 2009). Of note, the aP2 driver
expresses 200 times more Cre than the PPARg trigenic system
driver in mature adipocytes (Figure S2D). We crossed this com-
bination with the aforementioned floxed b-catenin allele to
generate PPARg-tTA; TRE-Cre; fBC (P-BCA for progenitor
b-catenin activated) mice (Figure 2A). Western blots indicated
that the P-BCA genetic arrangement was effective; the faster-
migrating activated form of b-catenin was present in mutant
but not control (PPARg-tTA; TRE-Cre or PPARg-tTA; fBC)
adipose tissue, and also not in other tissues (Figures 2B and 2C).
We next examined 3.5- to 4.5-month-old P-BCA mice for
possible adipose phenotypes; sibling controls contained the
PPARg-tTA allele, as well as either TRE-Cre or fBC (PPARg-tTA;
TRE-Cre or PPARg-tTA; fBC). P-BCAmice hadmarkedly reduced
fat (Figures 2D–2H). MRI scans indicated absence of subcuta-
neous (SQ) white adipose tissue accompanied by a dramatic
reduction of visceral depots (Figure 2D). NMR fat content analyses
showed a >80% fat reduction, similar to that seen in 4-month-old
PPARg null mice (Figure 2E). These PPARg null mice contain
a PPARg-tTA null allele, a PPARg floxed allele, and Sox2-Cre;
the latterexpressesCre in theepiblast, deletingPPARg inembryos
and mice but not in extraembryonic tissues (Hayashi et al., 2002).
ThesePPARg nullmicewere created in a similar fashion, and have
a similar lipodystrophic phenotype, to themice described byMor-
tensen and colleagues (Duan et al., 2007). P-BCA adiponectin
levels were undetectable and leptin levels were 1% of controls
(Figure 2F). Explanted P-BCA visceral fat was significantly small
(Figures 2G and 2H). However, in contrast to the MRI and NMR
analyses indicating absence of SQ fat (Figures 2D and 2E), the
SQ depots were of the same size and weight as controls (Figures
2G and 2H). The size of other organs, for example, kidney and
heart, were unchanged (Figure S2E, not shown).
Progenitor b-Catenin Activation Appears to Induce
a Fate Change
The results of the MRI and NMR studies—showing a marked fat
reduction—and the normal size and weight of the SQ adiposeell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc. 493
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Figure 1. b-Catenin Activation in Mature Adipocytes Does Not Alter Adiposity or Glucose Homeostasis
(A) Schematic of mature adipocyte cell-autonomous activation of b-catenin using aP2-Cre. Maroon arrowheads represent LoxP sites.
(B) Western blot of control (CON) and A-BCA mutant inguinal adipose depot extracts using an anti-b-catenin antibody. Slower-migrating bands represent wild-
type form (b-Catenin); faster-migrating bands represent the activated form of b-catenin (BCA).
(C) qPCR analysis of Wnt target gene Axin2 in the stromal vascular fraction (SV) and adipocyte fraction of control and A-BCA mice.
(D) MRI of control and A-BCA mice. Arrows indicate subcutaneous (SQ) adipose depots; arrowheads indicate visceral (VIS) adipose depots. Anterior (A);
Posterior (P).
(E) Weight and percent body fat (from NMR spectroscopy) of control and A-BCA siblings.
(F) Explants of inguinal (IGW) and perigonadal (PGW) adipose depots of control and A-BCA siblings.
(G) Weights of the indicated adipose depots of control and A-BCA mice. IGW, inguinal white adipose tissue (WAT); ISCW, intrascapular WAT; RPW, retroper-
itoneal WAT; PGW, perigonadal WAT; MWAT, mesenteric WAT.
(H) Histological sections of control and A-BCAmutant inguinal (IGW) and perigonadal (PGW) depots stained with hematoxylin and eosin (H&E). Size bar = 100 mm.
(I) Histological sections of control and A-BCA skin stained with H&E.
(J and K) Control and A-BCA serum levels of adiponectin and leptin (J) and insulin and triglyceride (TG) (K).
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Wnt Signaling Controls a Fat-Muscle Endocrine Axisdepots were discordant. This difference was also evident upon
palpation, which indicated that although the P-BCA SQ depots
had appropriate morphology, they did not have normal adipose
texture; rather, they were hard and rubbery. P-BCA SQ depots
had increased density, sinking in water (Figure 3A). P-BCA
inguinal (IGW) adipose tissue showed dense, eosin-positive
fibers that had the appearance of collagen (Figure 3B). Brown
adipose tissue was either absent or contained small fibrotic
remnants (Figure S3A). The few remaining visceral P-BCA
adipocytes were hypertrophied, potentially due to increased
demand for lipid storage (Figure 3B). Trichrome collagen staining
showed fibrotic SQ and subdermal adipose depots, and almost
no adipocytes (Figures 3C and S3B). P-BCA IGW had reduced
expression of adipocyte lineage genes (e.g., PPARg, leptin),
and expression of fibroblast markers (e.g., DDR2, Fsp-1) and
b-catenin targets (e.g., Wisp2) (Figures 3D and 3E). Although
P-BCA perigonadal (PGW) adipose tissue had increased expres-
sion of b-catenin targets, expression of adipose lineage or
fibroblastic markers were not significantly altered (Figure S3C).
To test if b-catenin activation altered adipose progenitor
lineage decisions, we labeled the progenitors by crossing a
TRE-H2B-GFP (H2B, Histone 2B) reporter into P-BCA mice. In
this system, H2B-GFP is stably incorporated into the chromatin
of adipose lineage cells (Tang et al., 2008, 2011; Zeve et al.,
2009). If cells within the lineage continue to express PPARg,
GFP is expressed. However, if the number of progenitors is
reduced or if PPARg expression is blunted, for example
secondary to fate changes, GFP expression is reduced (Fig-
ure 3F) (Tang et al., 2008, 2011; Zeve et al., 2009). We found
that P-BCA IGW had much less GFP fluorescence, and presum-
ably reduced PPARg expression or adipose lineage formation,
but that PGW depots had normal fluorescence (Figure 3G).
Flow cytometric analyses showed that P-BCA SQ depots had
fewer progenitors (Figure 3H).
To test the possibility that Wnt activation changed the fate of
adipose progenitors into a fibroblastic lineage, we crossed
a rosa26-flox-stop-flox-lacZ (R26R) allele into P-BCA mice (Sor-
iano, 1999; Tang et al., 2008) thereby indelibly marking adipose
progenitor cells and all descendants (Figure 3I) (Tang et al., 2008,
2011; Zeve et al., 2009). Notably, the cells present within the
fibrotic tissues expressed lacZ—and therefore derived from
a PPARg-positive cell—and contained high levels of nuclear
b-catenin (Figures 3J, 3K, and S3D). Thus, the cells present
within the fibrotic depots express fibroblastic markers, descend
from the adipose lineage, and have an activated Wnt pathway.
To further investigate a possible adipose progenitor fate
change, we isolated SQ SVF from control and P-BCA mice,
cultured the cells in adipogenic conditions, and then stained
them with Oil Red O as an indicator of adipogenesis. P-BCA
mutant SVF failed to differentiate (Figure 3L). qPCR analyses
after induction confirmed the adipogenic blockade and showed
high levels of Wnt targets, as well as preadipocyte (e.g., Pref-1)
and fibroblastic markers (Figure 3M). PPARg regulates the adi-(L) Blood glucose levels of fed or fasted (4 hr) control and A-BCA siblings.
(M) Glucose tolerance tests after a 4 hr fast of control and A-BCA siblings. Repres
cohorts. Female data also showed no effect elicited by the A-BCA mutation. Erro
t test, *p < 0.05. Genotypes: control = roughly equal mixture of aP2-Cre or fBC.
Cpogenic fate, and thus, to determine if the cells retained adipo-
genic potential, we infected control and P-BCA SQ SVF cells
with a virus expressing PPARg. However, PPARg infection of
P-BCA cells failed to rescue the adipogenic phenotype (Figures
3N and 3O).
P-BCA Mutants Do Not Develop Classical Metabolic
Consequences of Lipodystrophy
Lipodystrophy, the pathological reduction in fat content, is
accompanied by multiple metabolic disturbances, notably
hyperlipidemia and secondary ectopic lipid deposition (e.g., fatty
liver), insulin resistance and hyperglycemia (Fiorenza et al., 2010;
Garg, 2004). Based upon MRI and NMR analyses, as well as the
paucity of circulating adipokines such as adiponectin and leptin
(Figures 2D–2H), we reasoned that P-BCA mice were likely to
have lipodystrophic metabolic disturbances. Consistent with
that notion, the blood triglyceride (TG) levels of P-BCA mutants
were elevated at comparable levels to PPARg null mice, a lipody-
strophic model (Figure 4A). Surprisingly, however, liver histology
and triglyceride quantitation showed that P-BCAmutants did not
deposit fat in the liver, which, in lipodystrophic and hyperlipi-
demic models, is a typical storage site for excess triglycerides,
as seen in PPARg null livers (Figure 4B) (Fiorenza et al., 2010;
Garg, 2004). This unexpected absence of a hallmark lipody-
strophic consequence raised the possibility that glucose and
insulin homeostasis also might not show the typical lipody-
strophic hyperglycemia and hyperinsulinemia. Indeed, fed blood
glucose and insulin levels were similar between controls and
mutants and quite different from PPARg null lipodystrophic
mice (Figure 4C).
Next, we quantified food intake, movement, oxygen consump-
tion, and respiratory quotient (RQ). The P-BCA mice displayed
a modest increase in activity and food intake during the light
cycle when mice sleep (Figures 4D and 4E); however, oxygen
consumption was not statistically altered (Figure S4A). Further,
the RQ values indicated that carbohydrates, rather than fatty
acids, were preferentially utilized during that time (Figure S4B),
consistent with the increased food intake.
To investigate whether the increased RQ, activity, and food
consumption was due to fasting-induced hypoglycemia, we
quantified blood glucose at baseline and 1 hr after food removal.
Although initial fed glucose levels were equal, P-BCA mutants,
but not controls, lowered their blood glucose within 1 hr of
food withdrawal (Figure 4F). Glucose tolerance tests (GTTs)
also showed that P-BCA glucose levels were low, opposite of
classical lipodystrophy (e.g., PPARg null) (Figures 4G and 4H).
High insulin levels could explain the hypoglycemia. However,
fasting decreased serum insulin levels in parallel with reduced
blood glucose (Figure 4I). We quantified fasted serum levels of
other glucose regulatory molecules, including IGF-1, IGF-2,
glucagon, and growth hormone, but found no change compared
to controls, with IGF-2 undetectable in both control and mutant
sera (Figure 4J; not shown).entative studies on 4-month-old sibling males; nR 8 per cohort, repeatedR3
r bars indicate SEM. Statistical significance assessed by two-tailed Student’s
A-BCA = aP2-Cre; fBC.
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Figure 2. b-Catenin Activation in Adipose Progenitors Reduces
Adiposity
(A) Schematic of progenitor cell-autonomous activation of b-catenin (P-BCA)
using a tet transactivator (tTA) knocked-into exon 2 of the PPARg locus. In
PPARg-positive cells, tTA is translated and binds to a transgenic tet-response
element (TRE), inducing Cre expression and b-catenin activation. Maroon
arrowheads represent LoxP sites.
(B and C) Westerns of control (CON) and P-BCA inguinal adipose depots (B) or
livers and brains (C) assayed with anti-b-catenin and anti-tubulin antibodies.
b-catenin indicates wild-type form; BCA indicates activated form. Tubulin
serves as loading control. In (C), P-BCA adipose depot extracts are a BCA
positive control.
(D) MRI scans of control and P-BCA siblings. Arrows indicate normal location
of subcutaneous (SQ) adipose depots; arrowheads indicate visceral (VIS)
adipose depots. Anterior (A); Posterior (P).
(E) Left plots showweight and percent body fat (NMR spectroscopy), of control
and P-BCA siblings. Right plot is percent body fat of PPARg nulls (PPARg/)
and P-BCA mutants.
(F) Adiponectin and leptin levels of control and P-BCA sibling sera.
(G) Representative inguinal (IGW) and perigonadal (PGW) WAT explants of
control and P-BCA siblings.
(H) Weights of various adipose depots, as in Figure 1G, of control and P-BCA
siblings. Representative studies on 4-month-old sibling males; n R 8 per
cohort, repeatedR 3 cohorts. Female data mirrored these effects elicited by
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and Do Not Require Insulin for Reduced Blood Glucose
Increased sensitivity to insulin, rather than levels, could cause
fasting hypoglycemia. However, exogenous insulin reduced
glucose levels to the same extent in controls and mutants (Fig-
ure 5A). Next, we probed Akt phosphorylation, an indicator of
insulin signaling, before and 15 min after insulin injection.
Western blots of muscle extracts showed that insulin increased
the level of Akt phosphorylation, and that Akt phosphorylation
was not altered by the P-BCA mutation (Figure 5B). These data
indicate that the insulin responsiveness of P-BCA mutants was
unchanged and might not cause the observed hypoglycemia.
To investigate whether insulin action was required for the
paradoxical P-BCA hypoglycemia, we blocked insulin secretion
through two methods. In one, we infused somatostatin, a
hormone that inhibits secretion of insulin and glucagon (Sakurai
et al., 1974), and examined glucose levels during fasting and in
GTTs (Figure 5C). We used a dose of somatostatin that elimi-
nated insulin secretion in fasted mutants, but just decreased
insulin levels in controls, exploiting the lower fasting insulin levels
of themutants (Figures 4I and 5D). Thus, mutants would not have
the glucose-lowering effect of insulin, while controls would.
Nonetheless, food withdrawal still reduced P-BCA glucose
levels, and P-BCAmice had amuted response and a rapid return
to baseline in GTTs (Figure 5C). We also administered streptozo-
tocin (STZ), a small molecule that destroys insulin-producing
pancreatic beta cells (Pieper et al., 1999), to control and
P-BCA siblings. Consistent with b cell destruction, blood
glucose levels increased and insulin became almost undetect-
able (Figures 5E and 5F). Nonetheless, P-BCA mice given STZ
maintained a significantly lower blood sugar level in GTTs
compared to STZ controls (Figure 5E). These data indicate that
at least part of the observed hypoglycemia and increased
glucose tolerance is independent of insulin signaling.
Muscles of P-BCA Mutants Have Increased Glucose
Uptake and Increased AMPK and Glucose Transporter
Activity, but Unaltered Wnt Signaling
In a ‘‘fed GTT,’’ in which control and mutant siblings were chal-
lenged with a glucose load without prior fasting, P-BCA mutants
cleared glucose more efficiently than controls (Figure 6A). Next
we performed hyperinsulinemic euglycemic clamps in which
a constant amount of insulin is infused to increase and equalize
sera insulin along with a variable amount of glucose to maintain
blood glucose levels at a constant level of approximately
130 mg/dL (Figures 6B and S5). Once the glucose levels were
equalized, the glucose infusion rate (GIR) was five times higher
in mutants compared to controls (Figure 6C), indicating that
P-BCA mutants remove glucose from the blood at much higher
rates at equal sera concentrations of insulin. To examine which
tissues might have increased glucose uptake, we injected low
levels of 14C-labeled and metabolically inert 2-deoxy glucose
at the end of clamps and found that P-BCA skeletal and cardiac
muscles absorbed between two to four times more glucose than
control (Figure 6D).the P-BCA mutation. Error bars indicate SEM. Statistical significance
assessed by two-tailed Student’s t test, **p < 0.01.
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Figure 3. The P-BCA Mutation Induces a Lineage
Change in Subcutaneous Adipose Tissue
(A) Photograph of control (CON) and P-BCA inguinal
adipose depots (blue) in water. Arrow denotes air-water
interface.
(B) Hematoxylin and eosin (H&E) stained histological
sections of control and P-BCA IGW and PGW.
(C) Sections of control and P-BCA IGW and PGW stained
with trichrome (collagen stains blue).
(D) Fibroblast specific protein-1 (Fsp-1) immunohisto-
chemistry of P-BCA IGW. Top panel shows P-BCA IGW
negative control without primary antibody. Fsp-1 stained
dark brown (DAB); hematoxylin labels nuclei blue. Red
arrows indicate some Fsp-1-positive cells.
(E) qPCR of control (CON) and P-BCA IGW for the indicated
markers: PPARg is an adipogenic transcription factor;
adiponectin, Leptin, FAS, and LPL are adipocyte markers;
Col-1a1, Col-6a1, and DDR2 are fibroblast markers; Wisp2
is a Wnt target. nR 6 per cohort, repeatedR3 cohorts.
(F) Cartoon depicting PPARg-dependent marking of cells
using H2B-GFP (green) within PPARg-positive (PPARg+)
lineage using the tet-transactivator system (tTA). PPARg-
tTA drives expression of TRE-H2B-GFP. If the cell lineage
continues to express PPARg, they and their descendants
express GFP (green, top arrow path). If PPARg expression
is blunted, for example with a fate change, GFP expression
is diminished (bottom arrow path).
(G) GFP-fluorescent images of P-BCA and sibling IGW and
PGW.
(H) IGW SV cells were measured for percentage of GFP
positivity (y axis) with flow cytometry. The GFP+ gates set
based on controls with the TRE-H2B-GFP reporter alone.
nR 6 per cohort, repeatedR3 cohorts.
(I) Illustration of PPARg-dependent lacZ (blue) marking
within PPARg-positive (PPARg+) lineage using the tTA.
lacZ is an indelible marker in which Cre excises a tran-
scriptional stop cassette within the Rosa26 lacZ reporter
(R26R). Once a cell expresses PPARg-tTA and Cre (from
TRE-Cre allele), lacZ is permanently expressed, due to
removal of the stop cassette 50 of the lacZ gene, regardless
of PPARg expression in the cells and all descendants.
(J) Sections of X-gal stained P-BCA IGW.
(K) b-catenin staining of P-BCA IGW sections. Top panel
shows P-BCA IGW negative control without primary anti-
body. b-catenin stains dark brown (DAB); hematoxylin
stains nuclei blue. Red arrows indicate b-catenin positive
nuclei.
(L and M) SV cells of control and P-BCA sibling IGW were
isolated, cultured, and adipogenically induced. Adipo-
genesis was assayed with Oil Red O (L, fat stains red) and qPCR (M) of adipogenic (PPARg, C/EBPa, aP2, Adiponectin, Leptin, FAS, and LPL), preadipocyte
(Pref-1), fibroblast (DDR2), and Wnt target (Wisp2, Axin2) markers. nR 6 per cohort, repeatedR3 cohorts.
(N and O) SV cells were isolated from control and P-BCA siblings, infected with either empty or PPARg retrovirus and adipogenically induced. Adipogenesis
was assayed with Oil Red O (N) and qPCR (O). In (O), control (left graph) and P-BCA (right graph) IGW SVF infected with either mock or PPARg virus: PPARg and
C/EBPa are adipogenic transcription factors; Leptin, FAS, and LPL are adipocytemarkers. nR 6 per cohort, repeatedR3 cohorts. Scale bar = 100 mm. Error bars
indicate SEM. Statistical significance assessed by two-tailed Student’s t test, *p < 0.05, **p < 0.01.
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Wnt Signaling Controls a Fat-Muscle Endocrine AxisSkeletal muscle can increase glucose uptake through insulin-
dependent and -independent mechanisms (Steinberg and
Kemp, 2009). AMPK activation is a key mediator of the latter,
enhancing muscle glucose utilization during exercise (Fujii
et al., 2006). Since the glucose lowering effect observed in
P-BCA mice can occur in an insulin-independent manner (Fig-
ure 5), we examined the levels of AMPK activity, using western
blots for AMPK and acetyl-CoA carboxylase (ACC, an AMPK
target) phosphorylation in control and mutant muscles (Stein-
berg and Kemp, 2009). We found increased AMPK and ACCCphosphorylation in mutant muscles compared to controls in
both the fed and fasted milieu (Figure 6E). We also analyzed
p38 mitogen-activated protein kinase (MAPK), as it has been
shown to be involved in muscle glucose uptake (Chambers
et al., 2009; Lemieux et al., 2003; Somwar et al., 2000). Com-
pared to controls, P-BCA mutants have increased activation of
p38 MAPK, as measured by phosphorylation, without increased
insulin signaling, as measured by Akt phosphorylation (Fig-
ure 6E). To examine AMPK necessity, we injected P-BCA
mutants with vehicle or Compound C, an AMPK inhibitor (Zhouell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc. 497
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Figure 4. Paradoxically Improved Metabolism in Lipodystrophic
P-BCA Mutants
(A) Serum triglyceride levels of control and P-BCA siblings, and control and
PPARg null (PPARg/) siblings. Significance compared to sibling control.
(B) H&E stained sections of control, P-BCA, and PPARg null livers (top row
and bottom right panel). Bar graph of triglyceride quantification of control and
P-BCA liver extracts (bottom left panel).
(C) Random (FED) blood glucose (left) and serum insulin (right) levels of control
and P-BCA sibling and control and PPARg null sibling. Significance values
compared to sibling control.
(D and E) Food intake (D;mg food/day/mgmouse) and activity (X-Ymovement)
(E) during dark and light cycles.
(F) Blood glucose levels of control and P-BCA siblings at beginning and 1 hr
after food removal.
(G and H) GTT of control and P-BCA siblings (G) and control and PPARg null
siblings (H).
(I and J) Blood glucose (left) and serum insulin (right) levels (I) and sera
glucagon, growth hormone (GH) and insulin-like growth factor-1 (IGF1) (J) of
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rescued fasting-induced hypoglycemia, and induced fasting
hyperglycemia, which was exaggerated by GTT (Figures 6F–6H).
In muscle, AMPK and p38 MAPK increase glucose uptake by
stimulating the translocation of glucose transporters to the cell
surface (Lemieux et al., 2003; Steinberg and Kemp, 2009). To
explore such a potential mechanism we analyzed membrane
fractions of control and mutant muscles, from mice with or
without STZ treatment, for levels of glucose transporters. We
found that plasma membranes of P-BCA muscle had higher
levels of Glut4, and to a lesser extent Glut1, than controls
(Figures 6I), even in the absence of insulin.
We next addressed the possibility that the functional changes
observed in muscle were due to tissue-autonomous actions,
which could occur if the Cre driver was expressed in the
myogenic lineage. We first lineage traced the Cre driver using
the indelible Rosa26 marking system to assess the integrated
history of the driver in muscles during development and
adulthood. However, we did not detect significant muscle
X-gal staining (Figure 6J). Further, the faster-migrating activated
form of b-catenin observed in adipose tissue was not detected in
muscle extracts (Figure 6K). We also examinedWnt target genes
expression. However, qPCR analyses did not support the idea
that theWnt pathwaywas activated inmutantmuscle (Figure 6L).
These data indicate that Wnt activation at distance sites alters
muscle to increase glucose uptake in a nonautonomousmanner.
Mechanistically, this may occur via activation of AMPK and
p38 MAPK and increased glucose transporter cell-surface
localization.P-BCA Sera and P-BCA SV Cell-Conditioned Media
Increase Glucose Uptake in Wild-Type Muscle Explants
To further discriminate between intrinsic and extrinsic differ-
ences in P-BCAmuscles, we turned to an ex vivo glucose uptake
assay. We explanted sibling control and P-BCA tibialis anterior
(TA) and extensor digitorum longus (EDL) muscles—and at
time 0 assayed glucose uptake using radio-labeled 2-deoxyglu-
cose. We found that P-BCA muscles had increased glucose
uptake, mirroring the euglycemic clamps (Figures 6D and 7A;
not shown). We then assayed glucose uptake after control and
P-BCA muscles were incubated in wild-type (C57BL/6) sera for
3 hr. This preincubation equalized glucose uptake, indicating
that the in vivo changes might be secondary to extrinsic factors
(Figure 7A).
To test that notion, we isolated TA and EDLmuscles fromwild-
type C57BL/6 mice and incubated the explants in sibling control
sera and P-BCA sera, for either 1 or 3 hr, and then assayed
glucose uptake. We also included wild-type sera without or
with supra-physiological insulin (10003 fed sera concentra-
tion), as a positive control. At both times, P-BCA sera stimulated
glucose uptake significantly more than control sera, similar to
exogenous insulin (Figures 7B and 7C). We also evaluated thecontrol and P-BCA siblings 4 hr after food withdrawal. Representative studies
on 4-month-old sibling males; nR 8 per cohort, repeatedR3 cohorts. Female
data mirrors these effects elicited by the P-BCAmutation. Scale bar = 100 mm.
Error bars indicate SEM. Statistical significance assessed by two-tailed
Student’s t test, *p < 0.05, **p < 0.01.
eITT
120
CON
A B
%
 o
f 
ti
 G
lu
co
se
0
20
40
60
80
100 P-BCA
P(S473)Akt
tAkt
Vehicle Insulin
Min
0 30 60 90 120
Somatosta n Infusionti
300
400 CON
P-BCA
/d
L)
C D
1 5
2.0 CON
P-BCA
Somatosta n Infusionti
m
L)
0
100
200
0 50 100 150 200
**
** ***
*
*****
*
*
**
Gl
uc
os
e 
(m
g/
GTT
Min
0.0
0.5
1.0
.
- 03521
U
nd
et
ec
te
d
In
su
lin
 (n
g/
m
0 155
Min
400
600
800 CON-STZ P-BCA-STZ
CON-Veh P-BCA-Veh
**
*
*** **
100
150
200
se
 (m
g/
dL
)
Streptozotocin
te
d
**
in
 to
 C
on
tr
ol
E F
0
200
0 15 30 45 60 90 120
Min
###
#
# 0
50
Ins
Gl
uc
os
U
nd
et
ec
t
- STZ
P-BCACON
STZ
%
 In
su
l
CON
Figure 5. P-BCA Hypoglycemic Phenotype Is Not Due to Increased
Insulin Sensitivity
(A) Insulin tolerance test (ITT) of control and P-BCA siblings. nR 8 per cohort,
repeatedR3 cohorts.
(B) Akt western analysis of gastrocnemius muscle extracts 15 min after control
(C1-C4) and P-BCAmutant (M1-M4) mice were injected with either vehicle (left
panel) or insulin (right panel). p, phosphorylated; t, total.
(C and D) Glucose (C) and insulin (D) levels of control and P-BCAmale siblings
during somatostatin infusion. Somatostatin was infused at time 0. At 120 min
(red arrow) a bolus of glucose was injected with continued somatostatin
infusion. Bar graph of insulin levels at times 0 and 155 min (D). n R 10 per
cohort, repeatedR 2 cohorts.
(E and F) GTT and insulin levels of vehicle and streptozocin (STZ)-treated
control and P-BCA siblings 3 weeks after STZ administration. Insulin levels
normalized to -STZ control. Significance values compared to respective
controls without STZ treatment. n R 8 per cohort, repeated R2 cohorts.
Error bars indicate SEM. Statistical significance assessed by two-tailed
Student’s t test, * or # p < 0.05, ** or ## p < 0.01.
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Wnt Signaling Controls a Fat-Muscle Endocrine Axiswild-typemuscle explants for signaling 15min after incubation in
these conditions. We found that insulin increased Akt, but not
AMPK, phosphorylation (Figure 7D). In contrast, P-BCA sera
appeared to activate AMPK, but not Akt (Figure 7E).
To investigate the possibility that SQ adipose progenitors,
those cells that had undergone a lineage change, produced
the activity, we generated and cultured SV cells from SQ depots
of control and P-BCA littermates, and we collected conditioned
media. We incubated wild-type muscle explants in the condi-
tioned media and then assessed glucose uptake. The condi-Ctioned media from the P-BCA mutant cells increased glucose
uptake significantly more than control conditioned media (Fig-
ure 7F). Together, these studies indicate that the P-BCA mutant
sera and the P-BCA mutant SVF secretome contains a factor(s)
that acts upon muscles to activate AMPK and augment glucose
uptake, potentially accounting for aspects of the observed in vivo
P-BCA metabolic phenotypes (Figure 7G).
DISCUSSION
Metabolism and glucose homeostasis are regulated by interac-
tions, often mediated via nonautonomous signals, of many
tissues. Due to the inherent systemic dependencies, elucidation
of physiology and endocrine regulation often stems from
in vivo modeling. For example, the breakthrough discovery of
leptin and the role of adipose tissue as a key site of hormone
production and secretion relied upon mouse models followed
over decades by physiological and molecular understanding
(Friedman, 2010).
To investigate underpinnings of metabolic biology, we utilized
genetic modeling. When canonical Wnt signaling was altered
within mammalian adipose progenitor cells and throughout
the lineage, several distinct phenotypes were produced. For
example, there appeared to be adipose depot specificity.
Although the fat content of both subcutaneous and visceral
depots was severely diminished, the manner in which this
occurred was qualitatively distinct. The mutant visceral depots
were significantly smaller than controls, while subcutaneous
adipose tissues were of normal size. The disparity between
the lack of triglyceride accumulation and the absence of adipo-
cytes, yet characteristic SQ depot morphology, is reconciled
by replacement of the adipocyte lineage by fibroblastic cells.
Notably these fibroblastic lineage cells derived from the adipose
progenitor compartment, indicating that SQ progenitor fate is
regulated by Wnt signals.
A-BCA within mature adipocytes did not produce discernable
metabolic effects while a PPARg driver (P-BCA) in adipose pro-
genitor cells produced striking metabolic phenotypes. Perhaps
the most surprising results of altering Wnt signaling within the
adipose progenitor compartment were the anomalous constella-
tion of phenotypes that seem paradoxical to reports on classical
lipodystrophy (Longo et al., 2004; Savage, 2009; Wright et al.,
2007). Although P-BCA mice lacked adipose triglyceride accu-
mulation, with hypertriglyceridemia that mirrored classical lipo-
dystrophies, ectopic fatty acid accumulation and hyperglycemia
were notably absent. Rather, the mice appeared protected from
toxic fatty deposition and were hypoglycemic.
Since understanding glucose homeostasis has important
ramifications, we explored both the physiological and the
molecular underpinnings of the seemingly idiosyncratic P-BCA
glucose levels using a series of static, dynamic, and provocative
tests. Increased muscle glucose uptake appeared to be an
important catalyst of the improved glucose homeostasis. This
enhanced glucose absorption can occur independently of insulin
action. The physiological studies pointed to a testable mecha-
nistic hypothesis: Were AMPK and p38 MAPK, both of which
can increase glucose uptake in muscle independently of insulin
action, activated in P-BCA muscles? Biochemical studies sup-
ported this notion, as the mutant muscles had increasedell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc. 499
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Figure 6. Increased Glucose Uptake in P-BCA Muscles with Activation of AMPK, but Not Wnt signaling
(A) Fed GTT of control and P-BCA mutant mice. nR 8 per cohort, repeatedR3 cohorts.
(B–D) Hyperinsulinemic-euglycemic clamps of control and P-BCA siblings. Insulin and glucose infusions were started at time 0, 5 hr after food removal. Blood
glucose levels (B) and glucose infusion rate (GIR) (C) 15 min before and during clamp. Glucose uptake of indicated muscles (D) (Vastus = vastus medialis,
Gastroc = gastrocnemius) derived from isotope incorporation 30 min after injection of 14C 2-deoxyglucose at time 120 min of clamp. n R 10,
repeatedR2 cohorts.
(E) Western blots of proteins isolated from fed and fasted (4 hr) sibling 4-month-old male gastrocnemius muscles probed with the indicated antibodies.
C = control, M = P-BCA mutant, p = phosphorylated, t = total.
(F) AMPK blots of gastrocnemius muscles of P-BCA siblings injected with vehicle (P-BCA-Veh) or Compound C (P-BCA-CC). p, phosphorylated; t, total.
(G) Fasting blood glucose levels of P-BCAmales injected with vehicle (P-BCA-VH) or Compound C (P-BCA-CC). Mice were injected with vehicle or Compound C
at time 0 then fasted for 3 hr.
(H) GTT of P-BCA males injected with vehicle (P-BCA-VH) or Compound C (P-BCA-CC) and fasted for 4 hr.
(I) Fractionation of cytoplasm and plasmamembrane from limbmuscles of control (C1-C4) and P-BCA (M1-M4)male siblings bothwith andwithout STZ. Cadherin
and the insulin receptor (IR) are plasma membrane markers; tubulin is a cytoplasm marker.
(J) IGW and muscles of control (CON) and P-BCA mice were removed and incubated in X-gal. Blue color reflects lacZ expression.
(K) Western blot of muscle extracts of four control and four P-BCA siblings probed with anti-b-catenin and anti-tubulin antibodies. b-catenin indicates wild-type
form; BCA indicates activated form. Tubulin serves as loading control. P-BCA adipose depot extracts are BCA positive control.
(L) qPCR of control and P-BCA muscle extracts for the indicated b-catenin targets. nR 8 per cohort, repeatedR3 cohorts. Error bars indicate SEM. Statistical
significance assessed by two-tailed Student’s t test, *p < 0.05, **p < 0.01.
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Figure 7. Serum-Borne Factor Increases Glucose Uptake in Muscle
(A) Ex vivo glucose uptake assay of sibling control (CON) and P-BCA muscles
either immediately after excision (left portion, immediate) or 3 hr after incu-
bation in C57BL/6 (wild-type) serum (right portion, late). n R 4 per cohort,
repeatedR2 cohorts.
(B and C) Glucose uptake of C57BL/6 (WT) TA and EDL muscle explants
incubated for one hour in: sibling control (CON) or P-BCA sera (B) or C57BL/6
(WT) serawith vehicle (Veh) or insulin (Ins, 1U/ml) (C). nR 4muscles per cohort,
nR 3 sera per study, for control and P-BCA sera repeatedR10 cohorts.
(D and E) Western blots of proteins isolated from C57BL/6 (WT) muscles
incubated in WT sera with vehicle (WT1-Veh, WT2-Veh) or insulin (WT1-Ins,
WT2-Ins, 1U/ml) (C) or in sibling control (C1-S, C2-S) or P-BCA sera (M1-S,
M2-S) (D) for 15 min and probed with indicated antibodies. p = phosphory-
lated, t = total.
(F) Glucose uptake of WT TA and EDL muscle explants (1- to 2-month-old)
incubated for 1 hr in conditioned media of SV cells derived from sibling control
or P-BCA SQ adipose depots. nR 4 muscles per cohort, nR 3 conditioned
media per cohort, repeatedR3 cohorts.
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CAMPK and p38 MAPK activity, along with increased plasma
membrane localization of glucose transporters.
Since the implications of a possible nonautonomous signal-
altering muscle function are significant, we examined the possi-
bility that the Wnt pathway was altered within the myogenic
lineage per se through a variety of studies. However, lineage
tracing and molecular analyses did not support that idea. To
further investigate possible extrinsic signals, we established an
organotypic culture system for measuring intact muscle glucose
uptake. With this ex vivo system we found that the increase in
glucose uptake in the mutant muscles was present immediately
after placing the explants in culture, mirroring the euglycemic
clamp, but thereafter was reversible. That is, the increase in
glucose uptake did not appear intrinsic to the muscles, pointing
to the presence of a possible hormonal factor. Indeed, cultures
of wild-type muscle incubated in mutant sera had significant
increases in glucose uptake and AMPK activation, but not Akt
activation, compared to control sera.
Previous studies have illuminated an active communication
network between adipose tissue and muscle to regulate glucose
homeostasis. The adipokines adiponectin and leptin can in-
crease muscle insulin sensitivity and glucose uptake, through
indirect and direct means (Tomas et al., 2002; Toyoshima
et al., 2005). However, the levels of these two hormones were
markedly diminished or undetectable in P-BCA mutant sera,
supporting the possibility that other such factors may derive
from the mutant adipose depots, from adipose lineage cells
residing in other locations, and/or from nonadipose lineage.
The importance of testing such a notion is further highlighted
by the possibility that the PPARg-tTA, TRE-Cre driver may be
expressed in nonadipose tissues either nonspecifically or specif-
ically; PPARg is expressed in a variety of cell types (Michalik
et al., 2002). Thus, the use of the PPARg promoter/enhancer
elements confounds phenotypic interpretation, especially cells
of origin of the postulated glucose dynamics factor, as well as
whether the signal derives from adipose lineage cells. Another
potential complication is that adipose stem cells might reside
in nonadipose depot locales. Notable among these are reports
that adipose progenitors are present within skeletal muscle,
and that these cells can regulate muscle function (Joe et al.,
2010; Uezumi et al., 2010). Thus, it is possible that muscle-resi-
dent adipose progenitors could alter muscle glucose metabo-
lism via an intramuscular means. We attempted to probe the
possibility that the altered skeletal muscle glucose uptake might
be secondary to intrinsic effects with several methods including
lineage studies as well as with analyses of b-catenin recombina-
tion andWnt target gene activation. Although these studies were
negative, they are limited by detection sensitivity and other
factors. Ex vivo organotypic muscle glucose uptake assays
indicated that the increased muscle glucose uptake might(G) Model of P-BCA adipose tissue and muscle. P-BCA mice have increased
glucose uptake in muscle, increased glucose transporters at the myocyte cell
surface, and activated AMPK (blue arrows). The changes in muscle (e.g.,
increased glucose uptake, activated AMPK, and so on) are secondary to
a nonautonomous signal, for example a factor (glucose dynamics factor, blue
pentagon) secreted from the adipose stem cells in which b-catenin is acti-
vated. Error bars indicate SEM. Statistical significance assessed by two-tailed
Student’s t test, *p < 0.05, **p < 0.01.
ell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc. 501
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Wnt Signaling Controls a Fat-Muscle Endocrine Axisnot be intrinsic, as the effect was present immediately, but
thereafter was reversible. Ex vivo muscle studies also showed
that mutant sera could recapitulate in vivo hallmarks of the
P-BCA mice: increased glucose uptake and activation of
AMPK. Nonetheless, these studies do not exclude potential
intramuscular effects. Further, the secretion of the postulated
glucose dynamics factormay not derive from themutant adipose
tissue or b-catenin activation per se, as secondary changes in
peripheral tissues (e.g., liver, brain) could be responsible.
Notably, conditioned media from P-BCA SV cells, in which
adipose progenitors reside, stimulated glucose uptake signifi-
cantly more than control SV-conditioned media. Further
approaches, such as analyses of mutant adipose stem cells,
stem cell transplants, identification and expression analyses of
candidate factors, and further mechanistic dissection will be
required to define the signal, to determine its origin, and to delin-
eate how it functions. Taken together, our studies indicate that
blood glucose levels can be reduced via a nonautonomous
signal, possibly from Wnt-activated subcutaneous progenitors
or their derivatives or other adipose stroma-resident cells, that
increases AMPK activity and glucose uptake in muscle (Fig-
ure 7G) and provide a platform for discovery of the potential
glucose-regulatory factor.
EXPERIMENTAL PROCEDURES
Mouse Studies
The aP2-Cre, PPARg-tTA, TRE-Cre, fBC, TRE-H2B-GFP, and R26Rmice were
maintained as described and used to generate controls, A-BCA, P-BCA, and
lineage reporter mouse lines (Tang et al., 2008; 2011). Mice were fed normal
chow (4% fat, Teklad). Fat content was measured using a minispec mq10
NMR Analyzer (Bruker). For GTTs and ITTs, 1.25 mg glucose or 1.5 mU
Humalog (Lilly)/1 g mouse weight was injected intraperitoneally (IP) after
a 5 hr fast (for GTT) or during normal feeding (for fed GTT and ITT); blood
glucose levels were measured at the indicated intervals (Seo et al., 2009). To
induce a diabetic phenotype 0.2 mg STZ/1 g mouse was injected IP (Pieper
et al., 1999). To block AMPK activation 30 mg Compound C/kg mouse was
injected IP (Kim et al., 2004). Veterinary care provided by Division of
Comparative Medicine. Animals maintained under UT Southwestern Medical
Center Animal Care and Use Committee guidelines according to current NIH
guidelines.
Metabolic Phenotyping Experiments
Clamp studies were performed at the UT Southwestern Medical Center
Metabolic Core at Dallas based on previously described methods (Berglund
et al., 2008). In brief, mice were anesthetized (oxygen flow rate: 0.5–1 l/min
and isoflurane concentration: 2%–3%) and the jugular vein was catheterized.
Mice were monitored for 5 days, and mice that remained within 10% of the
presurgical body weight were studied. The clamp was started at t = 0 min
with a continuous insulin infusion (2.5 mU/kg/min) 5 hr after fasting. Glucose
was measured every 10 min for 2 hr to maintain euglycemia (130 mg/dL)
using a variable glucose infusion rate (GIR). 2-[1-14C]-deoxy-D-glucose was
administered at 120 min to measure tissue-specific glucose uptake. Tissues
were collected to determine glucose uptake, normalized to brain uptake. For
somatostatin experiments, catheterizedmice were fasted for 2 hr and somato-
statin (3 mg/kg/min) was infused at 0 min to prevent pancreatic secretion of
insulin and glucagon. A GTT was performed at 120 min.
Histology
Tissues were formalin fixed and paraffin embedded. Five to eight micron
sections were cut and stained with hematoxylin and eosin or trichrome. For
immunostaining, sections were deparaffinized, boiled in antigen-retrieval
solution, treated with b-catenin or Fsp-1 antibody, and stained with Vectastain
ABC KIT (Vector Laboratories) and DAB (ThermoScientific).502 Cell Metabolism 15, 492–504, April 4, 2012 ª2012 Elsevier Inc.qPCR
Total RNAwas extracted using TRIzol (Invitrogen), DNaseI treated, and reverse
transcribed with random hexamers; gene expression was analyzed using ABI
7500 Real-Time PCR System (Seo et al., 2009) and values normalized by
b-actin expression. Primer sequences available upon request.
Westerns
Immunoblotting was performed according to standard procedures (Seo et al.,
2005). Protein was extracted using PhosphoSafe Extraction Reagent (Calbio-
chem), boiled, separated on denaturing polyacrylamide gels, and transferred.
Membranes were blocked and incubated with primary antibodies (total and
phospho [Thr 172] AMPK, total and phospho [Ser 79] ACC, total and phospho
[Thr 180/ Tyr 182] p38 MAPK, total and phospho [Ser 473] Akt, insulin receptor
[IR], cadherin, b-catenin, Glut4, and tubulin from Cell Signaling Technology;
Fsp-1 and Glut1 from Abcam), washed, and incubated with secondary
antibodies conjugated with HRP (Jackson ImmunoResearch). Signals were
detected with chemiluminescent kits (NEN).
Cell Fractionation
Fractionation was performed as previously described with slight modification
(Carvalho et al., 2004). Muscle tissue from hind legs of control and P-BCAmice
were removed, frozen, powdered, suspended in HB buffer (20 mM Tris, 1 mM
EDTA, 255 mM sucrose, pH 7.4), and homogenized. The supernatant was
centrifuged at 16,000 g for 20 min after tissue debris was removed. The pellet
was resuspendedwith HBbuffer and centrifuged on 1.12M sucrose cushion at
100,000 g for 15 min. Plasma membrane fraction was collected from the inter-
face, diluted with HB buffer, and centrifuged at 200,000 g for 15 min. The pellet
was resuspended in SDS lysis buffer, sonicated, and centrifuged, and the
supernatant was used as plasma membrane fraction.
Isolation of Adipose Progenitor Cells
Floating adipocytes and SV cells were isolated as described (Tang et al., 2008).
Cell Culture
SV cells were cultured in DMEM with 10% FBS, 100 units/ml penicillin, and
100 mg/ml streptomycin. For induction, confluent wells were maintained in
growth media supplemented with 1 mg/ml insulin for about 1 week. Oil Red
O staining was performed as described (McKay et al., 2003). Recombinant
retroviral production and transduction was performed as described (Suh
et al., 2006). For conditioned media, the SV cells were cultured to confluence
and themedia was collected every 24 hr. In each conditioned media study, the
SV cells were from at least three control and three mutant siblings.
Ex Vivo Muscle Glucose Uptake
Intact TA and EDL muscles are from C57BL/6 or sibling controls, or P-BCA
mutants were dissected. For glucose uptake assays, the muscles were incu-
bated in the indicated conditions, rinsed, placed into 100 ml of glucose-free
DMEM containing 2-deoxy-glucose and 3H-2-deoxy-glucose for 20 min and
rinsed in ice-cold PBS, radioactive-incorporation assessed in scintillation fluid,
and normalized to muscle weight. In the various sera incubations, the left or
right muscle of the same mouse was placed into either control or the test
condition, these include wild-type C57BL/6 sera or B6 sera containing 0.1 U
insulin (Humalog, 40,000 ng/ml), as well as sibling control or P-BCA mutant
sera. In each study, muscles were obtained from at least four mice per group,
and sera were from at least three different mice.
X-Gal Staining
X-gal staining was performed as described (Tang et al., 2008).
Statistical Analysis
Statistical significance assessed by two-tailed Student’s t test. Error bars
indicate SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and can be found with this
article online at doi:10.1016/j.cmet.2012.03.010.
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